Long-term Efficacy and Safety of Subjects Approximately 3 Years After Priming With 2 Doses of GSK Bio's HRV Vaccine.

Clinical trial NCT00420316 · COMPLETED

Trial details

NCT number: NCT00420316
Sponsor: GlaxoSmithKline
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Infections, Rotavirus

Start date: 2007-02-12
Primary completion: 2007-08-08
Enrollment: 1613

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.